AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29939261 — intervention group
Group type: EXPERIMENTAL
Intervention: EA inoculated with LAB + 5% of molasses (EABM)
Number of subjects: 6
Study 29939261 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐h wilted EA (WEA)
Number of subjects: 6
Study 27052934 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVEOS navigation
Number of subjects: 78
Study 27052934 — intervention group
Group type: COMPARATOR
Intervention: Freehand positioning
Number of subjects: 78
Study 23575879 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral omega-3 fatty acids supplements for 12 weeks
Number of subjects: 101
Study 23575879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 22303592 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg twice daily)
Number of subjects: 8
Study 22303592 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose pill twice daily)
Number of subjects: 8
Study 18301124 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR (once-daily equivalent dose)
Number of subjects: 497
Study 18301124 — intervention group
Group type: COMPARATOR
Intervention: quetiapine IR (twice-daily)
Number of subjects: 497
Study 18301124 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR
Number of subjects: 497
Study 18301124 — intervention group
Group type: COMPARATOR
Intervention: quetiapine IR
Number of subjects: 497
Study 18301124 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR and IR
Number of subjects: 497
Study 17142407 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 81
Study 17142407 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 81
Study 14503897 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT plus telephone counselling (5 sessions)
Number of subjects: 854
Study 14503897 — intervention group
Group type: COMPARATOR
Intervention: NRT alone
Number of subjects: 854
Study 10699894 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy based on the combination of cisplatin and etoposide
Number of subjects: 75
Study 10699894 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and PC resection
Number of subjects: 75
Study 10699894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathology of the resected specimen
Number of subjects: 75
Study 10699894 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of disease (mediastinal only vs. visceral metastases)
Number of subjects: 75
Study 10699894 — intervention group
Group type: EXPERIMENTAL
Intervention: PC tumor markers
Number of subjects: 75
Study 9068554 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal lavage solution (3 L)
Number of subjects: 60
Study 9068554 — intervention group
Group type: COMPARATOR
Intervention: Fasting alone (control group)
Number of subjects: 60
Study 8403120 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia/analgesia
Number of subjects: 55
Study 8403120 — intervention group
Group type: COMPARATOR
Intervention: Parenteral analgesia with morphine
Number of subjects: 55
Study 2944913 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 4
Study 2944913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31931550 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis with 2.5 mg fondaparinux for 5 days postoperatively
Number of subjects: 133
Study 31931550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 31931550 — intervention group
Group type: COMPARATOR
Intervention: Control group (Placebo)
Number of subjects: 133
Study 31931550 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 133
Study 29575241 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self‐management delivered by diabetes specialist nurses plus treatment as usual
Number of subjects: 82
Study 29575241 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 82
Study 29575241 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self‐management
Number of subjects: 82
Study 27593728 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 150
Study 27593728 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 150
Study 25149199 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported appetite scores measured by Visual Analogue Scales (VAS)
Number of subjects: 549
Study 25149199 — intervention group
Group type: EXPERIMENTAL
Intervention: Without hunger as a factor
Number of subjects: 549
Study 22234979 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of anxiety at baseline (OR 1.11; 95% CI 1.03 to 1.19, p=0.006) among people free of FGID at baseline.
Number of subjects: 1775
Study 22234979 — intervention group
Group type: COMPARATOR
Intervention: FGID at baseline (no elevated anxiety and depression)
Number of subjects: 1775
Study 22234979 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of anxiety and depression at baseline in IBS
Number of subjects: 1775
Study 22234979 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression at baseline in FD
Number of subjects: 1775
Study 21189774 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg) and submucosal fentanyl (3 microg/kg)
Number of subjects: 23
Study 21189774 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg/kg) and submucosal placebo
Number of subjects: 23
Study 18721122 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation combined with passive stretching (30 min of electrical stimulation of the quadriceps 3 times per week and passive stretching of the hamstrings 5 times per week)
Number of subjects: 11
Study 18721122 — intervention group
Group type: COMPARATOR
Intervention: Passive stretching of the hamstrings (5 times per week)
Number of subjects: 11
Study 16397516 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (ARB)
Number of subjects: 0
Study 16397516 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (CCB)
Number of subjects: 0
Study 16397516 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 0
Study 16397516 — intervention group
Group type: COMPARATOR
Intervention: Losartan, Valsartan, Irbesartan (other ARBs)
Number of subjects: 0
Study 12707646 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antigenic suspension
Number of subjects: 9
Study 12707646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11069371 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 104
Study 11069371 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 104
Study 8823335 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus pamidronate 45 mg in 250 mL of saline as a 1‐hour intravenous infusion every 3 weeks
Number of subjects: 295
Study 8823335 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 295
Study 8823335 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus pamidronate
Number of subjects: 295
Study 1418071 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg/d)
Number of subjects: 402
Study 1418071 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (800 mg/d)
Number of subjects: 402
Study 1418071 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (75 mg/d)
Number of subjects: 402
Study 1418071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 3965269 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (acute administration)
Number of subjects: 34
Study 3965269 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (chronic administration, 35‐51 days)
Number of subjects: 34
Study 3965269 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 34
Study 3965269 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 30021756 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural S-equol supplement (10 mg a day, orally, twice daily for three menstrual cycles)
Number of subjects: 124
Study 30021756 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally, twice daily for three menstrual cycles)
Number of subjects: 124
Study 26525214 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (Pd-103)
Number of subjects: 630
Study 26525214 — intervention group
Group type: COMPARATOR
Intervention: Brachytherapy (Pd-103) + supplemental external beam radiotherapy (EBRT)
Number of subjects: 630
Study 25633713 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CpG-B + GM-CSF
Number of subjects: 28
Study 25633713 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CpG-B
Number of subjects: 28
Study 25633713 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 28
Study 22985432 — intervention group
Group type: EXPERIMENTAL
Intervention: dexpramipexole 300 mg/day
Number of subjects: 0
Study 22985432 — intervention group
Group type: COMPARATOR
Intervention: dexpramipexole 50 mg/day
Number of subjects: 0
Study 20873594 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarelin
Number of subjects: 122
Study 20873594 — intervention group
Group type: COMPARATOR
Intervention: Triptorelin
Number of subjects: 122
Study 18239661 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (MPH) 0.5 mg/kg
Number of subjects: 14
Study 18239661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16357400 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (fixed-duration injection protocol, 38 sec duration)
Number of subjects: 318
Study 16357400 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (fixed-rate injection protocol, 3 or 4 mL/sec)
Number of subjects: 318
Study 16357400 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (fixed-duration injection protocol, 47 sec duration)
Number of subjects: 318
Study 16357400 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 318
Study 15004969 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR)
Number of subjects: 134
Study 15004969 — intervention group
Group type: COMPARATOR
Intervention: Culture tests
Number of subjects: 134
Study 15004969 — intervention group
Group type: COMPARATOR
Intervention: Luminescence microscopy
Number of subjects: 134
Study 10881893 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine stent implantation
Number of subjects: 479
Study 10881893 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty with provisional stenting
Number of subjects: 479
Study 9190140 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day
Number of subjects: 40
Study 9190140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg/day
Number of subjects: 40
Study 1301244 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 27
Study 1301244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3009368 — intervention group
Group type: EXPERIMENTAL
Intervention: 6000 cGy irradiation
Number of subjects: 376
Study 3009368 — intervention group
Group type: COMPARATOR
Intervention: 5000 cGy irradiation
Number of subjects: 376
Study 3009368 — intervention group
Group type: COMPARATOR
Intervention: 4000 cGy irradiation (split course)
Number of subjects: 376
Study 3009368 — intervention group
Group type: COMPARATOR
Intervention: 4000 cGy irradiation (continuous course)
Number of subjects: 376
Study 3009368 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000-6000 cGy irradiation with tumor control
Number of subjects: 376
Study 3009368 — intervention group
Group type: COMPARATOR
Intervention: 5000-6000 cGy irradiation with intrathoracic failure
Number of subjects: 376
Study 3009368 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 cGy (split course) with tumor control
Number of subjects: 376
Study 3009368 — intervention group
Group type: COMPARATOR
Intervention: 4000 cGy (split course) without tumor control
Number of subjects: 376
Study 3009368 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 cGy (continuous course) with tumor control
Number of subjects: 376
Study 3009368 — intervention group
Group type: COMPARATOR
Intervention: 4000 cGy (continuous course) without tumor control
Number of subjects: 376
Study 3009368 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of irradiation
Number of subjects: 376
Study 3009368 — intervention group
Group type: EXPERIMENTAL
Intervention: Local tumor control at 12 months in advanced tumors (T4 or N3)
Number of subjects: 376
Study 3009368 — intervention group
Group type: COMPARATOR
Intervention: Thoracic failures in advanced tumors (T4 or N3)
Number of subjects: 376
Study 31439367 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented press-fit Regenerex® Porous Titanium Construct tibial tray and matching cemented patella and femoral components (hybrid implant)
Number of subjects: 80
Study 28477718 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventionists with <50 previous procedures
Number of subjects: 313
Study 28477718 — intervention group
Group type: EXPERIMENTAL
Intervention: More experienced interventionists
Number of subjects: 313
Study 28477718 — intervention group
Group type: COMPARATOR
Intervention: Strict selection of patients
Number of subjects: 313
Study 26084556 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose 400 mg albendazole
Number of subjects: 1010
Study 26084556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1010
Study 23908568 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (2.5 mg)
Number of subjects: 16
Study 23908568 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (1 mg)
Number of subjects: 16
Study 21859920 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking school bus program
Number of subjects: 149
Study 21859920 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study 19190051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless Oxford unicompartmental knee replacement
Number of subjects: 62
Study 19190051 — intervention group
Group type: COMPARATOR
Intervention: Cemented Oxford unicompartmental knee replacement
Number of subjects: 62
Study 17116941 — intervention group
Group type: COMPARATOR
Intervention: FEC (fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 1999
Study 17116941 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-D (three cycles of FEC followed by three cycles of docetaxel)
Number of subjects: 1999
Study 17116941 — intervention group
Group type: COMPARATOR
Intervention: FEC
Number of subjects: 1999
Study 17116941 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-D
Number of subjects: 1999
Study 15489850 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic and transesophageal echocardiography
Number of subjects: 0
Study 11351141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (ChE‐Is) including donepezil
Number of subjects: 423
Study 11351141 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 423
Study 11351141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 423
Study 11351141 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 423
Study 9542575 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 396
Study 9542575 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily
Number of subjects: 396
Study 8195995 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc phosphate
Number of subjects: 0
Study 8195995 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin‐glass ionomer hybrid
Number of subjects: 0
Study 8195995 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin‐glass ionomer hybrid with a dentinal bonding agent
Number of subjects: 0
Study 3370922 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of alpha‐methyldopa
Number of subjects: 13
Study 3370922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3370922 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of alpha‐methyldopa
Number of subjects: 13
Study 29580264 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training and physical exercise
Number of subjects: 0
Study 29580264 — intervention group
Group type: COMPARATOR
Intervention: Cognitive control and physical exercise
Number of subjects: 0
Study 29580264 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training and physical exercise control
Number of subjects: 0
Study 29580264 — intervention group
Group type: COMPARATOR
Intervention: Cognitive control and physical exercise control
Number of subjects: 0
Study 27505322 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 72
Study 27505322 — intervention group
Group type: COMPARATOR
Intervention: Control (sham RIPC)
Number of subjects: 72
Study 27505322 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPC
Number of subjects: 72
Study 25700856 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered applied relaxation
Number of subjects: 0
Study 23981878 — intervention group
Group type: EXPERIMENTAL
Intervention: Budget for purchasing WASH-related items
Number of subjects: 70
Study 23981878 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional funding for hiring a WASH attendant and making repairs to WASH infrastructure
Number of subjects: 70
Study 23981878 — intervention group
Group type: EXPERIMENTAL
Intervention: Guides for student and community monitoring of conditions
Number of subjects: 70
Study 23981878 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 21911944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil pulling with sesame oil
Number of subjects: 20
Study 21911944 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash
Number of subjects: 20
Study 18989992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebicapone 50 mg
Number of subjects: 16
Study 18989992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebicapone 100 mg
Number of subjects: 16
Study 18989992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebicapone 200 mg
Number of subjects: 16
Study 18989992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17015525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse ratings
Number of subjects: 36
Study 17015525 — intervention group
Group type: COMPARATOR
Intervention: Attending physician ratings
Number of subjects: 36
Study 14530474 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 30
Study 14530474 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 30
Study 10952746 — intervention group
Group type: EXPERIMENTAL
Intervention: Radon and carbon dioxide baths (1.3 kBq/l, 1.6 g carbon dioxide/l on average)
Number of subjects: 60
Study 10952746 — intervention group
Group type: COMPARATOR
Intervention: Sham control (artificial carbon dioxide baths)
Number of subjects: 60
Study 8828098 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin administration (Escherichia coli, Lot EC‐5, 4 ng/kg)
Number of subjects: 60
Study 8828098 — intervention group
Group type: COMPARATOR
Intervention: Antiendotoxin molecules
Number of subjects: 60
Study 8828098 — intervention group
Group type: COMPARATOR
Intervention: Mediator receptor antagonist
Number of subjects: 60
Study 8828098 — intervention group
Group type: COMPARATOR
Intervention: Antimediator therapy
Number of subjects: 60
Study 8828098 — intervention group
Group type: COMPARATOR
Intervention: Anti-inflammatory agents
Number of subjects: 60
Study 1580285 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4-8 mg/day)
Number of subjects: 54
Study 1580285 — intervention group
Group type: COMPARATOR
Intervention: Captopril (50-100 mg/day)
Number of subjects: 54
Study 6342352 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg intravenously followed by 200 mg daily orally for 3 months)
Number of subjects: 1395
Study 6342352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study 30833491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (250 mg at anesthetic induction and 250 mg at initiation of cardiopulmonary bypass)
Number of subjects: 7286
Study 30833491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7286
Study 28685884 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent Injection Drug Use (IDU)
Number of subjects: 400
Study 28685884 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual factors related to IDU
Number of subjects: 400
Study 25187158 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological treatment (specifics not provided)
Number of subjects: 35
Study 23981692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid 1 g 10‐min bolus followed by 1 g eight‐hour infusion
Number of subjects: 100
Study 23981692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19239602 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 103
Study 19239602 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 103
Study 15063813 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (30 mg per treatment) given at 3-month intervals for 12 months
Number of subjects: 50
Study 15063813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11590925 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug regimen with abacavir
Number of subjects: 0
Study 11590925 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-containing triple-drug combinations
Number of subjects: 0
Study 11590925 — intervention group
Group type: COMPARATOR
Intervention: PI-sparing regimens
Number of subjects: 0
Study 9591958 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg/day)
Number of subjects: 941
Study 9591958 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg/day)
Number of subjects: 941
Study 9591958 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alpha-tocopherol and beta-carotene
Number of subjects: 941
Study 9591958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 941